Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AZ's COVID-19 Antibody Combo Protects For Longer But Access Issues Persist

Positive Clinical Update On Evusheld

Executive Summary

AstraZeneca has presented more promising data from the PROVENT trial of its antibody combination therapy Evusheld which shows high levels of protection from COVID-19 for at least six months.

You may also be interested in...



AZ’s Evusheld Receives World-First Approval As COVID-19 Treatment, In Japan

Japan has approved Evusheld for both the prevention of infection in people who have not been exposed to the virus and, for the first time globally, as a treatment. The country's government will purchase 300,000 units from AZ amid global supplies that have been limited due to the surging need for the drug.

Coronavirus Update: Moderna’s Omicron Vaccine Study Successful, But Data Draw Skepticism

AstraZeneca also published efficacy data for Evusheld in patients with mild-to-moderate COVID-19, while Pfizer is investing $120m in expanding its Paxlovid manufacturing footprint in Michigan.

AstraZeneca’s Farxiga Flies Across $1bn Barrier

First-quarter sales jumped by 56% to $11.39bn at AstraZeneca and while its COVID-19 products brought in $1.6bn, it was the performance of the diabetes, heart failure and chronic kidney disease drug Farxiga that impressed most.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146262

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel